NCT06465199 2026-04-13
Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
Milton S. Hershey Medical Center
Phase 1/2 Recruiting
Clinical Trials
37 trialsNCT07468136 2026-04-13
Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas
Mayo Clinic
Phase 1/2 Not yet recruiting
NCT01349881 2026-04-02
PACES
SWOG Cancer Research Network
Phase 3 Active not recruiting
NCT07287917 2026-03-12
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
Aminex Therapeutics, Inc.
Phase 1/2 Recruiting
NCT06219174 2026-03-06
Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC (DFMO)
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Suspended
NCT04696029 2026-03-02
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
Milton S. Hershey Medical Center
Phase 2 Recruiting
NCT02559778 2026-02-20
PEDS-PLAN
Milton S. Hershey Medical Center
Phase 2 Recruiting
NCT03581240 2026-02-20
An Intermediate Expanded Use Trial of DFMO
Milton S. Hershey Medical Center
Available
NCT03794349 2026-02-18
Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma
Children's Oncology Group
Phase 2 Active not recruiting
NCT04301843 2026-02-03
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
Milton S. Hershey Medical Center
Phase 2 Recruiting
NCT02679144 2026-01-21
NMTT
Milton S. Hershey Medical Center
Phase 2 Recruiting
NCT06059118 2026-01-14
Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT07321912 2026-01-08
Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma
Milton S. Hershey Medical Center
Phase 2 Not yet recruiting
NCT04091022 2025-12-17
Topical Diclofenac and Topical DFMO Chemoprevention Trial in Subjects With a History of Skin Cancer
University of Alabama at Birmingham
Phase 2 Completed
NCT05717153 2025-11-04
Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma
Mayo Clinic
Phase EARLY_PHASE1 Recruiting
NCT05879367 2025-06-25
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
Orbus Therapeutics, Inc.
Phase 1 Recruiting
NCT06892678 2025-05-11
DFMO
Montefiore Medical Center
Phase 1/2 Recruiting
NCT02030964 2025-02-17
DFMO
New Approaches to Neuroblastoma Therapy Consortium
Phase 1 Completed
NCT02794428 2024-10-16
Chemoprevention of Gastric Carcinogenesis
Vanderbilt-Ingram Cancer Center
Phase 2 Completed
NCT01059071 2024-08-06
Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide
Milton S. Hershey Medical Center
Phase 1 Completed
NCT02395666 2024-08-06
Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission
Milton S. Hershey Medical Center
Phase 2 Completed
NCT02796261 2022-01-21
STELLAR
Orbus Therapeutics, Inc.
Phase 3 Unknown
NCT01483144 2021-06-08
Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)
Cancer Prevention Pharmaceuticals, Inc.
Phase 3 Completed
NCT00033371 2020-09-29
Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis
National Cancer Institute (NCI)
Phase 2 Completed
NCT00204789 2019-12-16
Difluoromethylornithine (DFMO) Chemoprevention of Skin Cancer in Organ Transplant Recipients
University of Wisconsin, Madison
Phase 2 Completed
NCT00005884 2019-12-13
Eflornithine to Prevent Skin Cancer in Patients With Previously Treated Early Stage Skin Cancer
University of Wisconsin, Madison
Phase 3 Completed
NCT00983580 2019-09-04
Acetylsalicylic Acid and Eflornithine in Treating Patients at High Risk for Colorectal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00006079 2018-10-25
Eflornithine To Prevent Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00021294 2018-09-11
Eflornithine With or Without Triamcinolone in Preventing Nonmelanoma Skin Cancer in Patients With Actinic Keratosis
University of Arizona
Phase 2 Completed
NCT00006101 2018-05-14
Eflornithine in Treating Patients At High Risk of Developing Prostate Cancer
University of California, Irvine
Phase 2 Completed
NCT00601640 2017-03-23
Eflornithine and/or Diclofenac in Treating Patients With Sun-Damaged Skin
University of Arizona
Phase 2 Completed
NCT01245816 2015-04-24
A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP)
Cancer Prevention Pharmaceuticals, Inc.
Phase 3 Withdrawn
NCT00118365 2015-01-22
Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps
National Cancer Institute (NCI)
Phase 3 Completed
NCT01636128 2014-07-30
Urinary Biomarker Study With Sulindac and Difluoromethylornithine
Cancer Prevention Pharmaceuticals, Inc.
Phase 2 Withdrawn
NCT00003814 2013-12-18
Eflornithine in Treating Patients With Bladder Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00086736 2013-11-19
Neoadjuvant Eflornithine and Bicalutamide Compared With Eflornithine Alone, Bicalutamide Alone, and No Neoadjuvant Therapy in Treating Patients With Localized Prostate Cancer Undergoing Brachytherapy or Radical Prostatectomy
University of Alabama at Birmingham
Phase 2 Completed
NCT00003076 2012-12-19
Eflornithine to Prevent Cancer in Patients With Barrett's Esophagus
University of Michigan Rogel Cancer Center
Phase 2 Completed